Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Multiplexed Protein Blood Test to Improve Prostate Cancer
Transcript
Atturos MBD Making Better Decisions Multiplexed Protein Blood Test to Improve Prostate Cancer Patient Decisions Steve Pennington Founder and CSO Imagine PSA14.2ng/ml DRE–abnormal Gleason3+4 Prostate Cancer What now? Decisions, Decisions, Decisions Radical Prostatectomy Radiation Treatment Active Surveillance 1 in 6 men are diagnosed with prostate cancer Most men die with not of prostate cancer Overtreatment is far too common Patient's treatment decision is a momentous one PSA, DRE and biopsy do not adequately support this life-changing decision Atturos’ Solution Multiplexed Protein Blood Test Organ Confined Blood Sample Non-Organ Confined Test Confinement Score Atturos’ Solution Multiplexed Protein Blood Test Organ Confined Non-Organ Confined UK Patent Application No. 1322800.2 for “PROSTATE CANCER BIOMARKERS” Blood Sample Test Confinement Score Market opportunity Over 1.2 million men are diagnosed with Prostate Cancer each year Market opportunity Over 1.2 million men are diagnosed with Prostate Cancer each year Atturos will initially target markets in N. America, UK and Ireland Market opportunity Atturos will initially target markets in N. America, UK and Ireland USA & Canada 250,000 diagnosed 25,000 active surveillance UK & Ireland 45,000 diagnosed 4,500 active surveillance Market opportunity 300,000-400,000 tests per annum Atturos will initially target markets in N. America, UK and Ireland USA & Canada 250,000 diagnosed 25,000 active surveillance UK & Ireland 45,000 diagnosed 4,500 active surveillance Route to Market 2016 2017 2018 2019 CS Assay V & CE 2020 2021 2022 Offer‘Confinement €? Score’testasservice CLIA MS lab CS Test in Use Marketing & Sales (Key Centres) IA Assay R&D IA Assay V & CE Offer‘InflammatoryArthriIs’ testasservice IA Test in Use Marketing & Sales (IA Network) Atturos MBD Atturos Vision Link molecular diagnostics with lifestyle informatics and patient monitoring Better clinical decisions for predictive and preventative healthcare Atturos MBD Highly experienced team with great track record Scalable solutions to meet clinical needs Investment opportunity in exciting new company [email protected] Atturos MBD Team MIKE FEENEY Chairman STEVE PENNINGTON Founder/CSO FERGUS FLEMMING COO STEVE FINN CMO [email protected] BRYAN MAGUIRE CFO
